YANA drospirenone 3 mg and ethinylestradiol 20 microgram film coated tablet blister pack Австралія - англійська - Department of Health (Therapeutic Goods Administration)

yana drospirenone 3 mg and ethinylestradiol 20 microgram film coated tablet blister pack

arrotex pharmaceuticals pty ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose; magnesium stearate; povidone; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - this medicine is indicated for use as: ? an oral contraceptive. ? treatment of moderate acne vulgaris in women who seek oral contraception. ? treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of drospirenone 3 mg /ethinylestradiol 20 ?g for pmdd was not assessed beyond 3 cycles. drospirenone 3 mg /ethinylestradiol 20 ?g has not been evaluated for treatment of pms (premenstrual syndrome), see section 5.1 pharmacodynamic properties - clinical trials.

FEMME-TAB 20/100 levonorgestrel 100mcg ethinylestradiol 20mcg film-coated tablet blister pack Австралія - англійська - Department of Health (Therapeutic Goods Administration)

femme-tab 20/100 levonorgestrel 100mcg ethinylestradiol 20mcg film-coated tablet blister pack

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 100 microgram; ethinylestradiol, quantity: 20 microgram - tablet, film coated - excipient ingredients: gelatin; macrogol 4000; magnesium stearate; maize starch; lactose monohydrate; titanium dioxide; hypromellose - oral contraception

FEMME-TAB 30/150 levonorgestrel 150mcg ethinylestradiol 30mcg film-coated tablet blister pack Австралія - англійська - Department of Health (Therapeutic Goods Administration)

femme-tab 30/150 levonorgestrel 150mcg ethinylestradiol 30mcg film-coated tablet blister pack

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: gelatin; hypromellose; iron oxide yellow; titanium dioxide; magnesium stearate; lactose monohydrate; maize starch; macrogol 4000 - oral contraception

FEMME-TAB ED 30/150 150mcg ethinylestradiol 30mcg film-coated tablet blister pack Австралія - англійська - Department of Health (Therapeutic Goods Administration)

femme-tab ed 30/150 150mcg ethinylestradiol 30mcg film-coated tablet blister pack

aft pharmaceuticals pty ltd - levonorgestrel, quantity: 150 microgram; ethinylestradiol, quantity: 30 microgram - tablet, film coated - excipient ingredients: titanium dioxide; iron oxide red; gelatin; maize starch; macrogol 4000; magnesium stearate; hypromellose; lactose monohydrate - oral contraception

TENOFOVIR EMT GH tenofovir disoproxil phosphate and emtricitabine 291mg/200mg film coated tablets Австралія - англійська - Department of Health (Therapeutic Goods Administration)

tenofovir emt gh tenofovir disoproxil phosphate and emtricitabine 291mg/200mg film coated tablets

lupin australia pty limited - emtricitabine, quantity: 200 mg; tenofovir disoproxil phosphate, quantity: 291 mg - tablet, film coated - excipient ingredients: mannitol; purified water; colloidal anhydrous silica; croscarmellose sodium; microcrystalline cellulose; stearic acid; titanium dioxide; lactose monohydrate; hypromellose; triacetin; indigo carmine aluminium lake - treatment of hiv-1 infection tenofovir emt gh is indicated for the treatment of hiv infected adults over the age of 18 years, in combination with other antiretroviral agents.,pre-exposure prophylaxis tenofovir emt gh is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in adults at high risk. this indication is based on clinical trials in men who have sex with men (msm) at high risk for hiv-1 infection and in heterosexual serodiscordant couples (see clinical studies).

ENTRESTO 49/51 sacubitril/valsartan (combined as a sodium salt hydrate complex) 48.6/51.4 mg film-coated tablet blister pack Австралія - англійська - Department of Health (Therapeutic Goods Administration)

entresto 49/51 sacubitril/valsartan (combined as a sodium salt hydrate complex) 48.6/51.4 mg film-coated tablet blister pack

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 51.4 mg; sacubitril, quantity: 48.6 mg - tablet, film coated - excipient ingredients: purified talc; colloidal anhydrous silica; crospovidone; titanium dioxide; hypromellose; hyprolose; macrogol 4000; magnesium stearate; iron oxide red; microcrystalline cellulose; iron oxide yellow - entresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

ENTRESTO 24/26 sacubitril/valsartan (combined as a sodium salt hydrate complex) 24.3/25.7 mg film-coated tablet blister pack Австралія - англійська - Department of Health (Therapeutic Goods Administration)

entresto 24/26 sacubitril/valsartan (combined as a sodium salt hydrate complex) 24.3/25.7 mg film-coated tablet blister pack

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 25.7 mg; sacubitril, quantity: 24.3 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; iron oxide red; titanium dioxide; macrogol 4000; hypromellose; hyprolose; magnesium stearate; microcrystalline cellulose; iron oxide black; purified talc - entresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

ENTRESTO 97/103 sacubitril/valsartan (combined as a sodium salt hydrate complex) 97.2/102.8 mg film-coated tablet blister pack Австралія - англійська - Department of Health (Therapeutic Goods Administration)

entresto 97/103 sacubitril/valsartan (combined as a sodium salt hydrate complex) 97.2/102.8 mg film-coated tablet blister pack

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 102.8 mg; sacubitril, quantity: 97.2 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; iron oxide black; magnesium stearate; titanium dioxide; iron oxide red; purified talc; crospovidone; hypromellose; macrogol 4000; hyprolose; microcrystalline cellulose - entresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

IMBRUVICA ibrutinib 560 mg film-coated tablet blister Австралія - англійська - Department of Health (Therapeutic Goods Administration)

imbruvica ibrutinib 560 mg film-coated tablet blister

janssen-cilag pty ltd - ibrutinib, quantity: 560 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; sodium lauryl sulfate; povidone; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - imbruvica is indicated for the treatment of patients with mcl who have received at least one prior therapy.,imbruvica as a single agent is indicated for the treatment of adult patients with waldenstr?m?s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.,imbruvica in combination with rituximab is indicated for the treatment of adult patients with waldenstrom?s macroglobulinaemia (wm).,imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (cll/sll).,imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (cll/sll) who have received at least one prior therapy.

IMBRUVICA ibrutinib 420 mg film-coated tablet blister Австралія - англійська - Department of Health (Therapeutic Goods Administration)

imbruvica ibrutinib 420 mg film-coated tablet blister

janssen-cilag pty ltd - ibrutinib, quantity: 420 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; sodium lauryl sulfate; povidone; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - imbruvica is indicated for the treatment of patients with mcl who have received at least one prior therapy.,imbruvica as a single agent is indicated for the treatment of adult patients with waldenstr?m?s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.,imbruvica in combination with rituximab is indicated for the treatment of adult patients with waldenstrom?s macroglobulinaemia (wm).,imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (cll/sll).,imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (cll/sll) who have received at least one prior therapy.